Follow us...


Search News Archives





View Channel

Laboratory Products



View Channel

Special Offers and Promotions


Microscopy | Image Analysis



View Channel

Separation Science



View Channel

Coronavirus (COVID-19)



View Channel

Research & Case Studies



View Channel

Conferences | Events

Quotient announces completion and publication of a RapidFACT program for Eli Lilly to develop an optimised drug product for new pain medication

Quotient Clinical, part of Quotient Bioresearch ("Quotient") today announced the publication of results, in the journal Pharmaceutical Research, of a RapidFACTTM program conducted for Eli Lilly

Quotient ClinicalThe integrated pharmaceutical development and clinical program was designed to develop an optimal controlled release (CR) formulation for the molecule LY545695 - a new potential medicine for the treatment of persistent pain.

The RapidFACT program achieved all of its objectives. An optimised drug product was delivered that matched the target exposure profile, and at a dose reduced by 30% in comparison with the drug product(s) that had been used in the earlier stages of development. Consequently, the cost of goods was significantly reduced for the drug product entering later stages of development. The entire program of work was delivered in less than nine months, resulting in significant timeline savings to the development project team. The program incorporated an innovative formulation design space to enable real-time optimisation of drug release rate with a high level of precision, in direct response to emerging clinical data.  Candidate formulations were also radiolabelled to allow real-time in vivo imaging of the dosage forms and confirmation of their location within the human gastrointestinal tract. 

Mark Egerton, Managing Director of Quotient Clinical, said: "This program of work is an excellent case study on how our innovative RapidFACT service can support and expedite a development program. Timelines were shortened, drug substance consumption was reduced, and the fact that all formulation selection decisions were based on human clinical data significantly increased precision. This RapidFACT program also incorporated scintigraphic assessment, which provided invaluable insights into formulation performance when GI location was integrated with pharmacokinetic data." 

The reference for the publication is Lobo ED, Argentine MD, Sperry DC, Connor, AL, McDermott JC, Stevens, LA, Almaya, A. Optimization of LY545694 Tosylate Controlled Release Tablets Through Pharmacoscintigraphy, Pharm Res. 2012; Online FirstTM, 14 June 2012

For further information or to discuss your specific needs, contact us on or visit

If you have not logged into the website then please enter your details below.


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month


Today's Picks




Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.